Janet Jill Hopkins Sells 11,822 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 11,822 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares in the company, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $8.75 on Thursday. The stock’s fifty day moving average price is $9.84 and its two-hundred day moving average price is $8.56. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38. The firm has a market cap of $437.07 million, a price-to-earnings ratio of -5.21 and a beta of 0.33.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. On average, equities analysts anticipate that Aura Biosciences, Inc. will post -1.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AURA has been the topic of several recent analyst reports. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. JMP Securities boosted their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, September 13th. BTIG Research boosted their target price on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $23.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AURA. American Century Companies Inc. acquired a new position in Aura Biosciences in the 2nd quarter valued at $119,000. American International Group Inc. lifted its position in shares of Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares during the period. Virtu Financial LLC bought a new stake in shares of Aura Biosciences during the 1st quarter valued at $144,000. SG Americas Securities LLC bought a new stake in shares of Aura Biosciences during the 3rd quarter valued at $169,000. Finally, Rhumbline Advisers lifted its position in shares of Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares during the period. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.